Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

1201P - Evaluation of efficacy TEMCAP regiment as first-line or further line therapy in patients with advanced, unresectable, progressive GEP-NET. Real-world data


21 Oct 2023


Poster session 13


Tumour Site

Neuroendocrine Neoplasms


Agnieszka Kolasinska-Cwikla


Annals of Oncology (2023) 34 (suppl_2): S701-S710. 10.1016/S0923-7534(23)01264-4


A.D. Kolasinska-Cwikla1, J. Cwikla2, J. Palucki3, M.A. Kawecki1, K. Marcisz-Grzanka1, K. Roszkowska-Purska4, K. Jakubowicz5, E. Chrapowicki5, L.S. Wyrwicz1

Author affiliations

  • 1 Department Of Oncology And Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 - Warsaw/PL
  • 2 Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-001 - Olsztyn/PL
  • 3 Department Of Radiology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 - Warsaw/PL
  • 4 Department Of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 - Warsaw/PL
  • 5 Department Of Surgical Oncology And Neuroendocrine Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 - Warsaw/PL


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1201P


Retrospective, single-institution study accessing the efficacy of TEMCAP regiment in pts. with advanced, unresectable progressive GEP-NET as a first or further lines after initial disease progression. Primary endpoint: progression-free survival (PFS), as initial with/without SST analogues previous therapy, PFS as second or further lines therapy using locally evaluation according to RECIST 1.1. Secondary goals: PFS in different subgroups and overall survival (OS).


54 pts with advanced unresectable, progressive GEP-NET. Mean age 58.0 (SD+/-12.4). All histological confirmed NETs: G1 n=10, G2 n=31, G3 n=13. Standard therapy approach using TEMCAP in all subjects. Disease status and treatment efficiency were evaluated according to localization of primary, initial vs. second or further line systemic therapy, bulky (>25% of liver volume) vs. not bulky liver disease, male vs. female, BMI ≤24 or BM I>24. Standard KM method used to assess PFS and OS for all subjects and in different subgroups. Cox regression model to assess any significant covariates of PFS and OS.


Pancreatic (panNET) n=32, midgut n=8; hindgut n=7 and 7 pts with CUP. PFS for all group 8.0 months (IQR 5.0-15.0), OS from initial diagnosis of GEP-NET 56.8 months (IQR 25.3-96.5); panNET n=32 -PFS=8.0 months (IQR 5.0-16.1), non-pancreas (n=22) PFS=6.2 (IQR 4.0-10.0), n.s. Initial therapy with TEMCAP n=24- PFS=9.2 (6.0-15.0) vs. second or further therapy n=30, PFS=6.0 (IQR 4.1-9.9) n.s. Bulky liver disease (n=31) PFS=7.9 (IQR 5.0-10.0) v.s. non-bulky liver disease (n=23) PFS=7.4 (IQR 4.4-17.0) n.s. Male (n=20) PFS=9.0 (IQR 5.7-15.0), vs. female (n=34) PFS=6.5 (IQR 5.0-11.5), n.s. Median BMI >24.0 PFS=7.0 (IQR 5.0-10.9), vs BMI≤24 PFS=9.0 (IQR 9.0-15.0), n.s. Cox Regression model did not find any significant predictor of improvement in PFS. In Cox regression model of OS indicated that high grade NET (G3) had HR=2.92 (CI 1.17-17.2) of death.


TEMCAP in real world data seems to be a good option in advanced, progressive GEP-NET with PFS=8 months, independently from the primary site, sex, BMI, liver involvement and previous therapy. Overall potential benefits in OS is seen in NETG1 or G2, but not in G3 with HR=2,92.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.